UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study

Annals of oncology, 2011-07, Vol.22 (7), p.1528-1534

2011

Volltextzugriff (PDF)

Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations

Anticancer research, 2003-03, Vol.23 (2C), p.1951

2003

Volltextzugriff (PDF)

Cetuximab for treatment of metastatic colorectal cancer

Annals of oncology, 2006-06, Vol.17 (suppl-7), p.vii66-vii67

2006

Volltextzugriff (PDF)

996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)

Annals of oncology, 2022-09, Vol.33, p.S1009

2022

Volltextzugriff (PDF)

Rationale and clinical results of multi-target treatments in oncology

The International journal of biological markers, 2007-01, Vol.22 (1 Suppl 4), p.S77-87

2007

Volltextzugriff (PDF)

EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S418-S419

2022

Volltextzugriff (PDF)

EP08.01-007 Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S338-S339

2022

Volltextzugriff (PDF)

Peritoneal carcinomatosis in non-small celllung cancer: retrospective multicentric analysis

Annals of oncology, 2016-09, Vol.27, p.iv14

2016

Volltextzugriff (PDF)

Rationale and clinical results of multi-target treatments in oncology

The International journal of biological markers, 2007, Vol.22 (4), p.77-87

2007

Volltextzugriff (PDF)

P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S675-S675

2021

Volltextzugriff (PDF)

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer

Annals of oncology, 2006-04, Vol.17 (suppl-2), p.ii49-ii51

2006

Volltextzugriff (PDF)

685TiPA phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v317

2019

Volltextzugriff (PDF)

685TiP - A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v317-v317

2019

Volltextzugriff (PDF)

TRKA expression and NTRK1 gene copy number across solid tumors

Annals of oncology, 2017-09, Vol.28, p.v600-v600

2017

Volltextzugriff (PDF)

Agnostos precision medicine project: a multicenter clinical and translational initiative in patients (PTS) with cancer of unknown primary (CUP)

Annals of oncology, 2016-09, Vol.27, p.iv123

2016

Volltextzugriff (PDF)

448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv148-iv149

2014

Volltextzugriff (PDF)

Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations

Annals of oncology, 2014-09, Vol.25, p.iv148

2014

Volltextzugriff (PDF)

Étude de phase II « basket » évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées présentant un réarrangement NRG1

Revue des maladies respiratoires actualités, 2020-01, Vol.12 (1), p.204-204

2020

Volltextzugriff (PDF)

Treatment of Metastatic Neuroendocrine Carcinomas Based on WHO Classification

Anticancer research, 2005-11, Vol.25 (6C), p.4463-4469

2005

Volltextzugriff (PDF)

Iron supplement in cancer patients receiving erythropoietin

Journal of clinical oncology, 2004-11, Vol.22 (21), p.4428; author reply 4428-4428

2004

Volltextzugriff (PDF)

PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

Value in health, 2007, Vol.10 (6), p.A333-A333

2007

Volltextzugriff (PDF)

Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

PharmacoEconomics. Italian research articles, 2007-07, Vol.9 (2), p.113-124

2007

Volltextzugriff (PDF)

Rationale and clinical results of multi-target treatments in oncology: Anti-epidermal growth factor receptor (EGFR) therapy: From science to clinical medicine

The International journal of biological markers, 2007, Vol.22 (1)

2007

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations

Cetuximab for treatment of metastatic colorectal cancer

996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)

Rationale and clinical results of multi-target treatments in oncology

EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

EP08.01-007 Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy

Peritoneal carcinomatosis in non-small celllung cancer: retrospective multicentric analysis

Rationale and clinical results of multi-target treatments in oncology

P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer

685TiPA phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

685TiP - A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

TRKA expression and NTRK1 gene copy number across solid tumors

Agnostos precision medicine project: a multicenter clinical and translational initiative in patients (PTS) with cancer of unknown primary (CUP)

448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS

Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations

Étude de phase II « basket » évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées présentant un réarrangement NRG1

Treatment of Metastatic Neuroendocrine Carcinomas Based on WHO Classification

Iron supplement in cancer patients receiving erythropoietin

PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

Rationale and clinical results of multi-target treatments in oncology: Anti-epidermal growth factor receptor (EGFR) therapy: From science to clinical medicine

Suchergebnisse filtern